These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Yu C; Rahmani M; Dent P; Grant S Exp Cell Res; 2004 May; 295(2):555-66. PubMed ID: 15093752 [TBL] [Abstract][Full Text] [Related]
64. Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. Shapovalov Y; Benavidez D; Zuch D; Eliseev RA Int J Cancer; 2010 Jul; 127(1):67-76. PubMed ID: 19894220 [TBL] [Abstract][Full Text] [Related]
65. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response. Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661 [TBL] [Abstract][Full Text] [Related]
66. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901 [TBL] [Abstract][Full Text] [Related]
67. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model. Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167 [TBL] [Abstract][Full Text] [Related]
68. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Ooi MG; Hayden PJ; Kotoula V; McMillin DW; Charalambous E; Daskalaki E; Raje NS; Munshi NC; Chauhan D; Hideshima T; Buon L; Clynes M; O'Gorman P; Richardson PG; Mitsiades CS; Anderson KC; Mitsiades N Clin Cancer Res; 2009 Dec; 15(23):7153-60. PubMed ID: 19934289 [TBL] [Abstract][Full Text] [Related]
69. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. Yu J; Tiwari S; Steiner P; Zhang L Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479 [TBL] [Abstract][Full Text] [Related]
70. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Mortenson MM; Schlieman MG; Virudachalam S; Lara PN; Gandara DG; Davies AM; Bold RJ Lung Cancer; 2005 Aug; 49(2):163-70. PubMed ID: 16022909 [TBL] [Abstract][Full Text] [Related]
71. Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo. Spiller SE; Logsdon NJ; Deckard LA; Sontheimer H BMC Cancer; 2011 Apr; 11():136. PubMed ID: 21492457 [TBL] [Abstract][Full Text] [Related]
72. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Fribley A; Zeng Q; Wang CY Mol Cell Biol; 2004 Nov; 24(22):9695-704. PubMed ID: 15509775 [TBL] [Abstract][Full Text] [Related]
73. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Ko BS; Chang TC; Chen CH; Liu CC; Kuo CC; Hsu C; Shen YC; Shen TL; Golubovskaya VM; Chang CC; Shyue SK; Liou JY Life Sci; 2010 Jan; 86(5-6):199-206. PubMed ID: 20006625 [TBL] [Abstract][Full Text] [Related]
74. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy. Balsas P; Galán-Malo P; Marzo I; Naval J Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467 [TBL] [Abstract][Full Text] [Related]
75. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122 [TBL] [Abstract][Full Text] [Related]
76. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Lioni M; Noma K; Snyder A; Klein-Szanto A; Diehl JA; Rustgi AK; Herlyn M; Smalley KS Mol Cancer Ther; 2008 Sep; 7(9):2866-75. PubMed ID: 18790767 [TBL] [Abstract][Full Text] [Related]
77. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420 [TBL] [Abstract][Full Text] [Related]
78. Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Bauer S; Parry JA; Mühlenberg T; Brown MF; Seneviratne D; Chatterjee P; Chin A; Rubin BP; Kuan SF; Fletcher JA; Duensing S; Duensing A Cancer Res; 2010 Jan; 70(1):150-9. PubMed ID: 20028860 [TBL] [Abstract][Full Text] [Related]
79. Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Elamin MH; Shinwari Z; Hendrayani SF; Al-Hindi H; Al-Shail E; Khafaga Y; Al-Kofide A; Aboussekhra A Mol Carcinog; 2010 Mar; 49(3):302-14. PubMed ID: 20025076 [TBL] [Abstract][Full Text] [Related]
80. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Gu H; Chen X; Gao G; Dong H Mol Cancer Ther; 2008 Aug; 7(8):2298-307. PubMed ID: 18723477 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]